ACIP Reported Conflicts Drop to 5% - RFK Jr. Still Fires All 17; Vaccine Stocks (PFE, MRNA, JNJ) Brace for Regulatory Noise

Robert F. Kennedy Jr.'s decision in June to remove all 17 members of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) drew headlines and accusations that the panel was riddled with financial conflicts. A fresh analysis published in a medical journal this week undercuts that narrative: reported conflicts on ACIP hit levels not seen since 2000.

The paper tracked yearly disclosures from 2000 through 2024 and found ACIP's annual reported conflict rate fell from about 42.8% at the turn of the century to roughly 5% in the most recent year. The research also looked at the Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee (VRBPAC), which has advised the FDA on vaccine approvals. VRBPAC's reported conflict rate has stayed under 4% since 2010; for ten of those years it was reported at zero.

Not all conflicts are created equal, the authors note. The most common disclosure was research funding - money that flows into labs and trials rather than into personal pockets. Ties that show up as direct personal income (consulting fees, royalties, stock holdings) have been rare: those types of disclosures have stayed below 1% for both committees since 2016.

Genevieve Kanter, who led the study, described a marked decrease in reported financial ties since the early 2000s. Another author, Peter Lurie, said in effect that while concern about conflicts is legitimate, the data don't back a claim of widespread financial entanglement on these advisory panels. The Department of Health and Human Services echoed the administration's stance: HHS said Kennedy is focused on removing both real and perceived conflicts and pointed to a new ACIP Conflicts of Interest Disclosures tool the agency rolled out this year.

Why traders should care - well, this isn't market advice, just facts: shifts in how advisory committees are staffed and perceived matter for regulatory certainty. Changes in perceived independence can affect the rhetoric around approvals and recommendations, which in turn can move shares in companies tied to vaccines and infectious-disease treatments. Firms commonly in that conversation include Pfizer (NYSE: PFE), Moderna (NASDAQ: MRNA) and Johnson & Johnson (NYSE: JNJ). When advisory panels look less conflicted on paper, headlines and political heat tend to cool - sometimes a modestly positive input for sector sentiment; when panels become a political football, uncertainty rises.

The timing of the firings - in the middle of a period when disclosure rates were low - has political and market implications beyond the numbers. Removing a full committee at once injects near-term opacity into how vaccine guidance will be formed. That can influence how traders price regulatory risk into companies developing new shots or updating existing vaccines.

Bottom line: the study's headline numbers are stark - ACIP down to roughly 5% reported conflicts in 2024, VRBPAC under 4% since 2010 with multiple zero years - and they complicate the argument that advisory panels were broadly compromised by financial ties. Whether the clearance of disclosed conflicts calms or rattles the market will depend on how the administration rebuilds these panels and how quickly normal advisory business resumes.

5% - that's the recent ACIP disclosure rate, the figure everyone debating the removals will be tossing around next.